-
1دورية أكاديمية
المؤلفون: Isla, Dolores, Lopez-Brea, Marta, Espinosa, María, Arrabal, Natalia, Pérez-Parente, Diego, Carcedo, DavidAff5, IDs1296202300417z_cor6, Bernabé-Caro, ReyesAff6, Aff7
المصدر: Cost Effectiveness and Resource Allocation. 21(1)
-
2دورية أكاديمية
المؤلفون: Dolores Isla, Marta Lopez-Brea, María Espinosa, Natalia Arrabal, Diego Pérez-Parente, David Carcedo, Reyes Bernabé-Caro
المصدر: Cost Effectiveness and Resource Allocation, Vol 21, Iss 1, Pp 1-11 (2023)
مصطلحات موضوعية: Atezolizumab, Cost-effectiveness analysis, IMpower110 trial, Non-small cell lung cancer, PD-L1 expression, Pembrolizumab, Medicine (General), R5-920
وصف الملف: electronic resource
Relation: https://doaj.org/toc/1478-7547
-
3مورد إلكتروني
مصطلحات الفهرس: Atezolizumab, Cost-effectiveness analysis, IMpower110 trial, Non-small cell lung cancer, PD-L1 expression, Pembrolizumab, info:eu-repo/semantics/article
URL:
https://hdl.handle.net/11441/144585 https://resource-allocation.biomedcentral.com/articles/10.1186/s12962-023-00417-z
Cost Effectiveness and Resource Allocation, 21 (1), 6.https://resource-allocation.biomedcentral.com/articles/10.1186/s12962-023-00417-z